Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 2 ( April-June, 2016 ) > List of Articles

RESEARCH ARTICLE

Therapeutic Role of Beta-blockers in Hypertension: A Pragmatic Reappraisal

Soumitra Kumar

Citation Information : Kumar S. Therapeutic Role of Beta-blockers in Hypertension: A Pragmatic Reappraisal. Hypertens J 2016; 2 (2):80-85.

DOI: 10.5005/jp-journals-10043-0036

Published Online: 00-06-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Kumar S. Therapeutic Role of Beta-blockers in Hypertension: A Pragmatic Reappraisal. Hypertens J 2016;2(2):80-85.


PDF Share
  1. A study of adrenergic receptors. Am J Physiol 1948;153(3):586-599.
  2. A new adrenergic beta-receptor antagonist. Lancet 1964 May 16;1(7342):1080-1081.
  3. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967 May 6;214(5088):597-598.
  4. Untoward effect associated with practolol administration: oculomucocutaneous syndrome. BMJ 1975 Mar 15;1(5958):595-598.
  5. Carvedilol. N Engl J Med 1998 Dec 10;339(24):1759-1765.
  6. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double-blind, cross-over study. Circulation 2001 Jul 31;104(5):511-514.
  7. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J Hypertens 1987 Oct;5(5):561-572.
  8. Primary prevention with metoprolol in patients with hypertension. JAMA 1988 Apr;259(13):1976-1982.
  9. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39, UK Prospective Diabetes Study Group. Brit Med J 1998 Sep 12;317(7160): 713-720.
  10. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3;290(21): 2805-2816.
  11. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002 Mar 23;359(9311):995-1003.
  12. Principal results of the Controlled Onset Verapamil Investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003 Apr 23-30;289(16): 2073-2082.
  13. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005 Sep 10-16; 366(9489):895-906.
  14. Differential impact of blood pressure –lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFÉ) study. Circulation 2006 Mar 7;113(9):1213-1225.
  15. Are Betablockers efficacious as first line therapy for hypertension in the elderly? JAMA 1998 Jun 17;279(23):1903-1907.
  16. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001 Oct;358(9290):1305-1315.
  17. Samuelsson O. Atenolol in Hypertension: is it a wise choice? Lancet 2004 Nov 6-12;364(9446): 1684-1689.
  18. Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis of randomized trials in the context of expectations from prospective epidemiological studies. BMJ 2009 May 19;338:1665-1684.
  19. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014 May;30 (Suppl 5):S47-53.
  20. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis [erratum in 2007;176:976]. CMAJ 2006 Jun 6;174(12):1737-1742.
  21. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003 Dec;42(6):1206-1252.
  22. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007 May 29;115(21):2761-2788.
  23. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982 Mar 26;247(12):1707-1714.
  24. Ten year mortality in relation to original size of myocardial infarct: results from the Golthenburg metoprolol study. Br Heart J 1994 Mar;71(3):238-241.
  25. Timolol-induced reduction in mortality and re-infarction in patients surviving acute myocardial infarction. N Engl J Med 1981 Apr 2;304(14):801-807.
  26. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICON randomized trial. Lancet 2001 May 5;357(9266):1385-1390.
  27. Beta-blocker therapy in heart failure. Scientific review. J Am Med Assoc 2002 Feb 20;287(7):883-889.
  28. The role of beta-blockers in preventing sudden death in heart failure. J Card Fail 2000 Jun;6(2 Suppl 1): 25-33.
  29. Beta-blockers in CHF: a Bayesian meta-analysis. Ann Intern Med 2001 Apr 3;134(7): 550-560.
  30. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005 Feb;26(3):215-225.
  31. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001 Mar;103(9):1245-1249.
  32. Does obesity modify the effect of blood pressure on the risk of cardiovascular disease? Circulation 2008 Oct 14;118(16):1637-1642.
  33. MRC trial of treatment of mild hypertension: principal results. BMJ 1985 Jul 13;291(6488): 97-104.
  34. Cardiovascular risk and risk factors in a randomized trial of treatment –based on the beta-blocker oxprenolol. J Hypertens 1985 Aug;3(4):379-388.
  35. Metoprolol versus diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991 Apr;17(4):579-588.
  36. Essential hypertension. Lancet 2007 Aug 18;370(9587):591-603.
  37. Paradoxic pressor effects of G-blockers in standing elderly patients with mild hypertension. Circulation 2002 Apr 9;105(14):1669-1671.
  38. Beta-blockers in hypertension: is carvedilol different? Am J Cardiol 2004 May 6;93(9A):7B-12B.
  39. The vasodilatory beta-blockers. Curr Hypertens Rep 2007 Aug;9(4):269-277.
  40. Metabolic profile of nebivolol, a beta adrenoceptor antagonist with unique characteristics. Drugs 2007;67(8):1097-1107.
  41. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001 May;37(5):1236-1241.
  42. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8(1):35-44.
  43. Evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014 Feb 5;311(5):507-520.
  44. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014 Jan;32(1):3-15.
  45. NICE hypertension guideline 2011:evidence based evolution. BMJ 2012 Jan 13; 344:e181.
  46. Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. Task Force Members 2013 ESH/ESC. Guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013 Jul;31(7):1281-1357.
  47. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2015 May;31(5):549-568.
  48. B-adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol 2010 Jun;10(3):254-259.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.